Baird's initiation reinforces the bullish consensus just ahead of earnings on July 15. The combination of insider buying and institutional accumulation supports the view that current levels offer an attractive entry. Traders can look for upside to the $115-$121 range into earnings.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $92.18entry
- T+1 · 5mo ago +3.49%α +3.62% · $95.40
- T+5 · 4mo ago +3.97%α +3.71% · $95.84
- T+20 · 4mo ago +17.16%α +19.35% · $108.00
- T+60 · 8w ago +9.64%α +6.69% · $101.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Baird initiated coverage on Abbott Laboratories (ABT) at Outperform with a $121 price target, implying 33% upside from the current $90.74. The firm has a 54% accuracy rate across 2,555 calls. Consensus is heavily bullish at 70.6% Buy (24 of 34 analysts), with a mean target of $116.54. The PT range spans $92 (low) to $135 (high). Recent EPS revisions have tilted slightly negative over 30 days, but insider buying of ~$1.3M in late April through early May signals confidence. Institutional activity shows large additions from Charles Schwab and Capital Research. With earnings due July 15, the call aligns with consensus direction but adds a fresh bullish catalyst. Bottom line: the initiation reinforces the value case at current levels.
Impact Score
Consensus & Targets
Of 34 analysts, 10 are Strong Buy, 14 Buy, and 10 Hold, giving a 70.6% bullish rating. No analysts rate Sell or Strong Sell. The consensus is firmly bullish.
Mean target $116.54, median $115, high $135, low $92. Current price $90.74 implies 28.4% upside to the mean. Baird's $121 PT sits above both the mean and median.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-01 | Baird | initiate | Outperform | $121.00 |
| 2026-06-22 | Piper Sandler | reiterate | Overweight | No target |
| 2026-04-27 | BTIG | reiterate | Buy | $131.00 |
| 2026-04-20 | Barclays | maintain | Overweight | $143.00 |
| 2026-04-17 | Piper Sandler | maintain | Overweight | $115.00 |
| 2026-04-17 | Oppenheimer | maintain | Outperform | $115.00 |
| 2026-04-17 | RBC Capital | maintain | Outperform | $130.00 |
| 2026-04-17 | Benchmark | maintain | Buy | $120.00 |
| 2026-04-17 | Evercore ISI Group | maintain | Outperform | $120.00 |
| 2026-04-17 | B of A Securities | maintain | Buy | $120.00 |
In the last 30 days, there has been 1 upgrade (this initiation) and 0 downgrades. EPS revisions show 1 upward revision for next quarter and 2 downward revisions for the current quarter and next year, a mixed but slightly negative tilt.
Firm Track Record: Baird
Baird accuracy: 54% on 2555 calls | avg return: 4%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Citigroup | 67% | 4/6 | 1.2% | top tier |
| Jefferies | 67% | 4/6 | 0.8% | top tier |
| Evercore ISI Group | 63% | 5/8 | 0.8% | top tier |
| RBC Capital | 56% | 5/9 | 1.8% | above average |
| Wells Fargo | 50% | 2/4 | -0.4% | below average |
| Goldman Sachs | 50% | 1/2 | 4.5% | below average |
| Barclays | 50% | 3/6 | 1.1% | below average |
| UBS | 50% | 1/2 | 1.3% | below average |
| Stifel | 50% | 1/2 | -0.9% | below average |
| BTIG | 40% | 2/5 | -3% | below average |
Baird has a 54% accuracy rate on 2,555 calls with a 4% average return. On this ticker, top-tier firms by accuracy include Citigroup (67% on 6 calls) and Jefferies (67% on 6). Baird's 54% is near the middle of the pack; worst performers include Bernstein (0% on 3) and Morgan Stanley (0% on 3).
Earnings Estimates
Next earnings: Jul 15, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $1.28 | $1.26 to $1.29 | $12.5B | ↑0 ↓0 |
| +1q | $1.42 | $1.40 to $1.45 | $13.1B | ↑1 ↓0 |
| 0y | $5.48 | $5.40 to $5.71 | $50.3B | ↑0 ↓0 |
| +1y | $6.06 | $5.95 to $6.20 | $54.8B | ↑0 ↓0 |
Cross-Platform Signals
Insider trades: three buys in April/May totaling ~$1.3M from executives including SVP Stratton and CFO Starks, a bullish signal. A small congressional sell by Rep. Gottheimer ($1K-$15K) is negligible. Institutional activity: large adds from Charles Schwab (+245%) and Capital Research (+27%), offset by Norges Bank exit and Invesco trim. Short interest of 3.07M shares with a 55% days-to-cover ratio is moderate.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
38 reports on ABT
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +17.05% at T+20 after the Oct 7, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $108.52 −1.28% settles Dec 7
- Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $108.52 +5.26% settles Nov 24
- Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $108.52 +5.73% settles Nov 25
- Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $108.52 +5.86% settles Nov 19
- Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
- Oct 21, 202626d ago 8-K Bearish 6/10 No price data
- Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
- Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
- Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $108.52 +4.29% ▲ +3.26% +6.72% vs SPY
- Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $108.52 +3.46% ▲ +3.46% +4.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers